Fluke Corporation, the global leader in portable electronic test and measurement technology, announces the availability of the Fluke® 430 Series II Three Phase Power Analyzers, the first tools to use a patented algorithm to measure energy wasted by power quality issues and quantify its cost. By providing the ROI data needed to justify power quality improvements, the 430 Series II helps facilities reduce electrical power consumption and improve the performance and lifespan of electro-mechanical equipment.
To view Multimedia News Release, go to MNR http://www.multivu.com/mnr/54283-fluke-435-three-phase-power-quality-analyzer-test-generators-motors
Children’s Memorial Hermann Hospital and Cord Blood Registry® (CBR) are launching the first FDA-approved, Phase I safety study on the use of cord blood stem cells to treat children with sensorineural hearing loss.
To view Multimedia News Release, go to http://www.multivu.com/mnr/53686-cord-blood-childrens-memorial-hermann-fda-approved-stem-cells-hearing-loss
Symptoms improved significantly in adults with the bleeding disorder hemophilia B following a single treatment with gene therapy developed by researchers at St. Jude Children’s Research Hospital in Memphis and demonstrated to be safe in a clinical trial conducted at the University College London (UCL) in the U.K.
The findings of the six-person study mark the first proof that gene therapy can reduce disabling, painful bleeding episodes in patients with the inherited blood disorder. Results of the Phase I study appear in the December 10 online edition of the New England Journal of Medicine. The research is also scheduled to be presented December 11 at the 53rd annual meeting of the American Society of Hematology in San Diego.
To view Multimedia News Release, go to http://www.multivu.com/mnr/46766-st-jude-children-s-research-hospital-gene-therapy-bleeding-disorder
The Ad Council, in partnership with the U.S. Department of the Treasury and the U.S. Department of Housing and Urban Development (HUD), have joined together to launch a new phase of their Foreclosure Prevention Assistance Public Service Advertising (PSA) Campaign. The campaign aims to increase awareness of the Making Home Affordable® Program’s free resources and assistance for homeowners who are struggling with their mortgage payments.
To view Multimedia News Release, go to http://www.multivu.com/mnr/51783-ad-council-making-home-affordable-english-psa
National Instruments (Nasdaq: NATI) today introduced a 14 GHz version of its NI PXIe-5665 high-performance RF vector signal analyzer (VSA), which delivers best-in-class dynamic range and accuracy in a cost-effective PXI form factor. The new VSA features industry-leading phase noise and dynamic range, regardless of form factor, including traditional rack-and-stack instruments. Because of its PXI platform, the VSA can deliver measurement speeds up to 20 times faster than box instruments and for less cost. Additionally, it takes advantage of multicore computing architectures and parallel programming capabilities through NI LabVIEW system design software. It also offers peer-to-peer data streaming for signal processing and a flexible multiple input, multiple output (MIMO) architecture for phase-coherent measurements. Such features make it ideal for demanding RF test applications including radio detection and ranging (RADAR), satellite, radio and harmonic testing.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/nationalinstruments/51200/
Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today that the U.S. Food and Drug Administration (FDA) has approved the company’s antibacterial drug DIFICID™ (fidaxomicin) tablets for the treatment of Clostridium difficile-associated diarrhea (CDAD) in adults 18 years of age and older. CDAD is a significant medical problem in hospitals and long-term care facilities, and is beginning to emerge in the community among people previously at low risk for the disease. In the largest Phase 3 clinical studies ever conducted in CDAD, DIFICID had clinical response rates at the end of treatment that were non-inferior to oral vancomycin. DIFICID was superior to vancomycin in sustaining clinical response through 25 days beyond the end of treatment. DIFICID is the only FDA-approved antibacterial drug proven to be superior to vancomycin in sustained clinical response for CDAD.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/optimerpharma/50177/
Baha Mar celebrated the commencement of construction with its official groundbreaking ceremony on Feb. 21, 2011. The largest single-phase resort development in the history of the Caribbean, the 1,000-acre, $3.4 billion resort, gaming and entertainment complex is slated to open in late 2014, and will include some of the world’s most famous hotel brands, setting a new standard of luxury for the hospitality industry.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/bahamar/48767/
Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced The New England Journal of Medicine has published results from the North American Phase 3 trial evaluating the safety and efficacy of the Company’s novel antibiotic fidaxomicin as a treatment for patients with Clostridium difficile infection (CDI). The Phase 3 trial showed that fidaxomicin significantly reduced recurrence rates and increased global cure rates when compared to vancomycin, the only treatment approved by the U.S. Food and Drug Administration for CDI. The article titled,
The University of Texas Health Science Center at Houston (UTHealth) has begun enrollment for the first Phase I safety study approved by the Food and Drug Administration to investigate the use of a child’s own umbilical cord blood stem cells for traumatic brain injury in children. The study is being performed in conjunction with Children’s Memorial Hermann Hospital, UTHealth’s primary children’s teaching hospital.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/cordblood/48021/
BlackRock, Inc. (NYSE: BLK) today announced that its iShares® Exchange Traded Funds (ETFs) business, the world’s largest manager of ETFs, is launching a campaign to assist investors in learning what to look for when selecting an ETF. The initial phase of the campaign is the publication of an Investor ETF Checklist and an accompanying educational video, both available on the iShares website.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/iShares/47109/
Bacardi Limited, the largest privately held spirits company in the world, today announced the initial phase of its US$250 million dollar investment in Scotch whisky production has been completed. This investment is to meet growing demand for the premium portfolio of Dewar’s Scotch whiskies, which are among the top-selling, favorite and most awarded Scotches in the world.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/bacardi/46020/
Taj Hotels Resorts & Palaces today announced the second phase of their brand architecture exercise with the roll-over of 19 hotels to their new brand, Vivanta by Taj Hotels & Resorts, slotted in the 5-Star Upper Upscale segment. India’s largest hospitality group flagged off Vivanta by Taj Hotels & Resorts at a gala event at the brand’s marquee hotel, Vivanta by Taj – Whitefield, Bangalore. This follows the highly successful launch of their Upscale brand - The Gateway Hotel - exactly two years ago.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/prne/ihc/44198/
